Plain English with Derek Thompson

Episode: Fraud, Scandal, and Failure in the Fight Against Alzheimer's Disease
Release Date: February 11, 2025

Introduction

In this compelling episode of Plain English with Derek Thompson, host Derek Thompson delves into the murky waters of Alzheimer's disease research, uncovering a web of fraud, scandal, and systemic failure that has hindered progress in finding a cure. Joined by journalist Austin Rivers, Thompson explores how misconduct within the scientific community, coupled with entrenched groupthink, has stymied advancements against one of the most devastating ailments of our time.

The Amyloid Hypothesis Dominance

[08:13] Austin Rivers

Austin Rivers begins by tracing the historical roots of Alzheimer's research, highlighting the rise of the amyloid hypothesis. Originating from Alois Alzheimer’s initial observations in 1906, the hypothesis posits that the accumulation of amyloid-beta proteins in the brain leads to Alzheimer's disease.

“In the early 90s, this was conceptualized into something called the amyloid cascade hypothesis… that amyloid plaques and other forms of amyloid protein start a cascade of biochemical effects in the brain that eventually leads to dementia.”
— Austin Rivers [08:38]

The hypothesis gained significant traction due to logical consistency with observed brain pathology and substantial funding from institutions like the National Institutes of Health (NIH). This influx of resources solidified amyloid-beta as the central target in drug development, overshadowing alternative theories.

Rising Doubts and Contradictions

[13:26] Austin Rivers

Despite its dominance, the amyloid hypothesis faced critical challenges. Rivers points out two major contradictions:

1. Presence in Asymptomatic Individuals: Amyloid plaques are found in many elderly individuals who never develop Alzheimer's symptoms, questioning the hypothesis’s exclusivity.
2. Clinical Trial Failures: Drugs targeting amyloid-beta successfully removed plaques but failed to improve cognitive functions, raising doubts about their therapeutic efficacy.

“Patients on the drug reportedly saw their memory improve after just one month. Other trials showed that patients' memory and anxiety improved by 10% and their cognitive test scores soared after just 9. The market responded with jubilation.”
— Austin Rivers [03:35]

These inconsistencies began to erode confidence in the amyloid hypothesis, suggesting that the scientific community might need to broaden its research focus.

The 2006 Nature Paper and Its Impact

[15:05] Austin Rivers

A pivotal moment came in 2006 with a groundbreaking paper published in Nature by the University of Minnesota scientists. The study introduced Amyloid Beta star 56, a specific form of amyloid-beta, demonstrating a direct causative effect on memory loss in animal models. This discovery reinvigorated the amyloid hypothesis, attracting billions in funding and cementing its role as the cornerstone of Alzheimer's research.

“This study was cited thousands of times. It became one of the most important and cited studies in Alzheimer's research for a period of 16 years until 2022.”
— Austin Rivers [17:35]

However, this paper's credibility would later come into question, revealing deeper issues within the research community.

Uncovering Fraud: Charles Piller's Investigation

[17:49] Austin Rivers

Journalist Austin Rivers collaborates with neuroscientist Matthew Schrag and other image integrity experts to investigate the authenticity of the 2006 Nature paper. Their scrutiny revealed potential image manipulation in the study's Western blots—key pieces of evidence purportedly supporting the amyloid hypothesis.

“The images were changed to reflect the experimental hypothesis. So it appeared… but more work needed to be done to find out for sure.”
— Austin Rivers [18:28]

Rivers' investigative reporting, published in Science, confirmed the fraudulent alterations, leading to the paper's retraction in June 2024 and the indictment of lead scientist Huyan Wong for research fraud.

“In June 2024, Nature retracts this famous paper for image doctoring… Huyan Wong… he's indicted on charges alleging research fraud.”
— Austin Rivers [23:17]

Wider Implications: Systemic Fraud in Alzheimer's Research

[24:26] Austin Rivers

The scandal extends beyond the retracted paper, exposing a pervasive pattern of misconduct among leading neuroscientists. Two notable cases include:

1. Berezlav Slakovich at USC: Found to have manipulated images across numerous studies, impacting stroke research and leading to the shutdown of a major clinical trial.

   “This scientist… was found to have been apparently engaging in image doctoring… the agency immediately stepped in and shut down the trial three days after the story appeared.”
   — Austin Rivers [30:02]

2. Eliza Maslia at NIH: The former director of the Division of Neuroscience was implicated in a vast network of falsified studies, resulting in over 132 studies being flagged for image manipulation and a staggering 18,000 citations contaminated by fraudulent data.

   “They found literally 132 studies that appeared to have been based on image manipulation… 18,000 citations to studies within these 132 that appeared to be based on tainted images.”
   — Austin Rivers [31:02]

These cases illustrate a broader issue within the field, where significant funding and authority have been leveraged to propagate fraudulent research, severely undermining trust and progress.

Groupthink and Its Consequences

[40:21] Austin Rivers

Beyond individual misconduct, Rivers discusses the role of groupthink in perpetuating the amyloid hypothesis. The dominance of a single theory creates a narrow focus, discouraging exploration of alternative pathways and fostering an environment where deviating from the consensus is professionally risky.

“They have to say, we believe we're going to have an effect in our understanding of amyloid proteins in the process of doing this experiment, even if their desire is to explore something else.”
— Austin Rivers [43:16]

This conformity not only stifles innovation but also makes the field more susceptible to fraud, as alternative theories receive less scrutiny and fewer resources.

The Cost of Fraud and Stagnation in Research

[37:38] Austin Rivers

The financial and societal costs of this widespread fraud are immense. Despite advancements in other medical fields, Alzheimer's research has lagged, partly due to the misallocation of funds based on falsified data.

“The combination of that, the difficulty of the problem, and some small amount of faked science that has skewed thinking in the field that is combined for a very tragic outcome that is very little progress.”
— Austin Rivers [37:38]

This stagnation has real-world implications, with increasing death rates from Alzheimer's contrasting with declining rates from other major diseases like cancer and heart disease.

Addressing the Fallout and Moving Forward

[50:29] Derek Thompson

As the scandal unfolds, calls for defunding scientific institutions emerge. However, Rivers cautions against such drastic measures, emphasizing that fraudulent actors constitute a tiny minority and that the overarching institution has been instrumental in numerous medical breakthroughs.

“The vast, vast majority of people in this field are honest and deeply determined to do the best work to solve the disease.”
— Austin Rivers [50:29]

Instead, he advocates for reforming scientific institutions to enforce stricter oversight, promote transparency, and encourage diverse research approaches to prevent future misconduct and groupthink.

Hopeful Horizons in Alzheimer’s Research

[51:31] Austin Rivers

Despite the setbacks, there are promising avenues for Alzheimer's research. Emerging studies on GLP1 inhibitors and the potential role of antiviral therapies offer new hope.

“There's a clinical trial going on that could prove out some of the potential benefits of GLP1 inhibitors… There's some very interesting work going on in exploring antiviral therapies.”
— Austin Rivers [51:31]

Additionally, lifestyle interventions targeting controllable risk factors like high blood pressure and cholesterol levels provide avenues for prevention and mitigation, empowering individuals to take charge of their health.

“There are several risk factors that we have a degree of control over in our lives… we can reduce the possibility of having the worst effects of Alzheimer's.”
— Austin Rivers [51:31]

Conclusion

Derek Thompson and Austin Rivers present a sobering yet hopeful narrative on the state of Alzheimer's research. While fraud and systemic issues have severely impeded progress, renewed scrutiny, diversified research approaches, and emerging scientific breakthroughs offer a path forward. The episode underscores the necessity of integrity and openness in scientific inquiry to overcome formidable challenges like Alzheimer's disease.

Notable Quotes

• Austin Rivers [08:13]: “In the early 90s, this was conceptualized into something called the amyloid cascade hypothesis… that amyloid plaques and other forms of amyloid protein start a cascade of biochemical effects in the brain that eventually leads to dementia.”

• Austin Rivers [17:35]: “This study was cited thousands of times. It became one of the most important and cited studies in Alzheimer's research for a period of 16 years until 2022.”

• Austin Rivers [31:02]: “They found literally 132 studies that appeared to have been based on image manipulation… 18,000 citations to studies within these 132 that appeared to be based on tainted images.”

• Austin Rivers [37:38]: “The combination of that, the difficulty of the problem, and some small amount of faked science that has skewed thinking in the field that is combined for a very tragic outcome that is very little progress.”

• Austin Rivers [51:31]: “There are several risk factors that we have a degree of control over in our lives… we can reduce the possibility of having the worst effects of Alzheimer's.”

Key Takeaways

• Fraudulent Practices: High-profile cases of image manipulation have severely undermined trust and progress in Alzheimer's research.

• Groupthink: The dominance of the amyloid hypothesis has stifled alternative research avenues, contributing to scientific stagnation.

• Systemic Issues: Institutional complacency and inadequate oversight have allowed misconduct to proliferate within the scientific community.

• Path Forward: Reforming scientific institutions, promoting research diversity, and embracing emerging theories offer hope for breakthroughs against Alzheimer's disease.

This episode serves as a critical examination of the challenges facing Alzheimer's research, emphasizing the need for vigilance, integrity, and innovation to overcome one of medicine's most daunting challenges.